invitrogen USER GUIDE

Human IL-33 ELISA Kit

Enzyme-linked Immunosorbent Assay for quantitative detection of human IL-33

Catalog Numbers BMS2048 and BMS2048TEN

Pub. No. MAN0016509 Rev. B.0 (31)



WARNING! Read the Safety Data Sheets (SDSs) and follow the handling instructions. Wear appropriate protective eyewear, clothing, and gloves. Safety Data Sheets (SDSs) are available from **thermofisher.com/support**.

Product description

The Human IL-33 ELISA Kit is an enzyme-linked immunosorbent assay for the quantitative detection of human IL-33.

Summary

IL-33 is the 11th and most recently discovered member of the IL-1 family of cytokines, which furthermore includes IL-1 α , IL-1 β , IL-18 and IL-1Ra. As with IL-1 β and IL-18, the synthesized 30 kDa propeptide IL-33 lacks a clear signal peptide for direct processing via the endoplasmic reticulum and Golgi apparatus. In vivo, caspase-1 cleaves the pro-IL-1 β and pro-IL-18 bioactive forms, an essential step for their subsequent secretion. The mechanism for IL-33 might be similar, but the process has not been fully elucidated yet. In vitro, caspase-1 can cleave human IL-33, which results in a 20-22 kDa mature form.

In humans, IL-33 mRNA is predominantly found in dermal fibroblasts, bronchial and small airway epithelial cells and smooth muscle cells of skin and lung tissues. Later, cellular mRNA expression has been observed in adipocytes, synovial fibroblasts, high endothelial venules, and endothelial cells. Furthermore, IL-33 is expressed in fibroblastic reticular cells of lymphoid tissues, skin keratinocytes, epithelial cells of stomach, tonsillar crypts and salivary glands, cardiac fibroblasts and cardiomyocytes. In most cells the predominant localization of IL-33 is nuclear rather than cytoplasmic. IL-33 specifically binds to IL1RL-1, which is known also as ST2, and is part of the IL-1R family.

IL-33 promotes the release of Th2-associated cytokines from in vitro polarized human and murine Th2 cells, and also acts as a Th2 chemotactic factor. IL-33-promoting cytokine production activates human basophils and probably also regulates their migration. IL-33 influence on activation, degranulation, enhanced adhesion and survival of eosinophils has been shown. Mast cells are well-studied responders to IL-33. The cytokine increases synthesis of IL-6, IL-13, IL-1 β , TNF α , prostaglandin D2 and MCP-1 by primary bone marrowderived mast cells. Other cells activated by IL-33 are cardiomyocytes, glial cells and CD34+ cells.

For literature update refer to our website.

Principles of the test

An anti-human IL-33 coating antibody is adsorbed onto microwells.




Fig. 1 Coated microwell

Human IL-33 present in the sample or standard binds to antibodies adsorbed to the microwells.




Fig. 2 First incubation

Following incubation unbound biological components are removed during a wash step. A biotin-conjugated anti-human IL-33 antibody is added and binds to human IL-33 captured by the first antibody.




Fig. 3 Second incubation

Following incubation unbound biotin- conjugated anti-human IL-33 antibody is removed during a wash step. Streptavidin- HRP is added and binds to the biotin- conjugated anti-human IL-33 antibody.




Fig. 4 Third incubation



Following incubation unbound Streptavidin-HRP is removed during a wash step, and substrate solution reactive with HRP is added to the wells.




Fig. 5 Fourth incubation

A colored product is formed in proportion to the amount of human IL-33 present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from 7 human IL-33 standard dilutions and human IL-33 sample concentration determined.




Fig. 6 Stop reaction

Reagents provided

Reagents for human IL-33 ELISA BMS2048 (96 tests)

1 aluminum pouch with a Microwell Plate (12 strips with 8 wells each) coated with polyclonal polyclonal antibody to human IL-33

1 vial (140 μ L) Biotin-Conjugate anti-human IL-33 polyclonal polyclonal antibody

1 vial (150 µL) Streptavidin-HRP

2 vials human IL-33 Standard lyophilized, 500 pg/mL upon reconstitution

1 vial (12 mL) Sample Diluent

1 vial (15 mL) Conjugate Diluent

1 vial (5 mL) Calibrator Diluent

1 vial (5 mL) Assay Buffer Concentrate 20x (PBS with 1% Tween $^{\text{™}}$ 20, 10% BSA)

1 bottle (50 mL) Wash Buffer Concentrate 20x (PBS with 1% Tween [™] 20)

1 vial (15 mL) Substrate Solution (tetramethyl-benzidine)

1 vial (15 mL) Stop Solution (1M Phosphoric acid)

6 Adhesive Films

Reagents for human IL-33 ELISA BMS2048TEN (10x96 tests)

10 aluminum pouches with a Microwell Plate (12 strips with 8 wells each) coated with polyclonal antibody to human IL-33

10 vials (140 $\mu L)$ Biotin-Conjugate anti-human IL-33 polyclonal antibody

10 vials (150 µL) Streptavidin-HRP

 $10\ \mathrm{vials}\ \mathrm{human}\ \mathrm{IL}\text{-}33\ \mathrm{Standard}\ \mathrm{lyophilized}, 500\ \mathrm{pg/mL}\ \mathrm{upon}\ \mathrm{reconstitution}$

6 vials (12 mL) Sample Diluent

10 vials (15 mL) Conjugate Diluent

5 vials (5 mL) Calibrator Diluent

3 vials (5 mL) Assay Buffer Concentrate 20x (PBS with 1% Tween $^{\text{\tiny TM}}$ 20, 10% BSA)

8 bottles (50 mL) Wash Buffer Concentrate 20x (PBS with 1% Tween 20)

10 vials (15 mL) Substrate Solution (tetramethyl-benzidine)

1 vial (100 mL) Stop Solution (1M Phosphoric acid)

30 Adhesive Films

Storage instructions - ELISA kit

Store kit reagents between 2° and 8°C. Immediately after use remaining reagents should be returned to cold storage (2° to 8°C). Expiry of the kit and reagents is stated on labels.

Expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, this reagent is not contaminated by the first handling.

Sample collection and storage instructions

Cell culture supernatant, serum, and plasma (citrate, heparin) were tested with this assay. Other biological samples might be suitable for use in the assay. Remove serum or plasma from the clot or cells as soon as possible after clotting and separation.

Samples containing a visible precipitate must be clarified prior to use in the assay. Do not use grossly hemolyzed or lipemic samples.

Samples should be aliquoted and must be stored frozen at -20° C to avoid loss of bioactive human IL-33. If samples are to be run within 24 hours, they may be stored at 2–8°C (for sample stability refer to "Sample stability" on page 6).

Avoid repeated freeze-thaw cycles. Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.

Materials required but not provided

- 5 mL and 10 mL graduated pipettes
- 5 µL to 1000 µL adjustable single channel micropipettes with disposable tips
- 50 μL to 300 μL adjustable multichannel micropipette with disposable tips
- Multichannel micropipette reservoir
- Beakers, flasks, cylinders necessary for preparation of reagents
- Device for delivery of wash solution (multichannel wash bottle or automatic wash system)
- · Microplate shaker
- Microwell strip reader capable of reading at 450 nm (620 nm as optional reference wave length)
- · Glass-distilled or deionized water
- Statistical calculator with program to perform regression analysis

Precautions for use

- All reagents should be considered as potentially hazardous. We
 therefore recommend that this product is handled only by those
 persons who have been trained in laboratory techniques and that it
 is used in accordance with the principles of good laboratory
 practice. Wear suitable protective clothing such as laboratory
 overalls, safety glasses and gloves. Care should be taken to avoid
 contact with skin or eyes. In the case of contact with skin or eyes
 wash immediately with water. See material safety data sheet(s)
 and/or safety statement(s) for specific advice.
- Reagents are intended for research use only and are not for use in diagnostic or therapeutic procedures.
- Do not mix or substitute reagents with those from other lots or other sources.
- Do not use kit reagents beyond expiration date on label.
- Do not expose kit reagents to strong light during storage or incubation.
- Do not pipet by mouth.
- Do not eat or smoke in areas where kit reagents or samples are handled
- Avoid contact of skin or mucous membranes with kit reagents or samples.

- Rubber or disposable latex gloves should be worn while handling kit reagents or samples.
- Avoid contact of substrate solution with oxidizing agents and metal.
- · Avoid splashing or generation of aerosols.
- To avoid microbial contamination or cross-contamination of reagents or samples that may invalidate the test, use disposable pipette tips and/or pipettes.
- Use clean, dedicated reagent trays for dispensing the conjugate and substrate reagent.
- Exposure to acid inactivates the conjugate.
- Glass-distilled water or deionized water must be used for reagent preparation.
- Substrate solution must be at room temperature prior to use.
- Decontaminate and dispose samples and all potentially contaminated materials as if they could contain infectious agents.
 The preferred method of decontamination is autoclaving for a minimum of 1 hour at 121.5°C.
- Liquid wastes not containing acid and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste containing acid must be neutralized prior to the addition of sodium hypochlorite.

Preparation of reagents

- Buffer Concentrates should be brought to room temperature and should be diluted before starting the test procedure.
- 2. If crystals have formed in the Buffer Concentrates, warm them gently until they have completely dissolved.

Wash buffer (1x)

- Pour entire contents (50 mL) of the Wash Buffer Concentrate (20x) into a clean 1,000 mL graduated cylinder. Bring to final volume of 1,000 mL with glass-distilled or deionized water. Mix gently to avoid foaming.
- 2. Transfer to a clean wash bottle and store at 2–25°C. The Wash Buffer (1x) is stable for 30 days.
- 3. Wash Buffer (1x) may also be prepared as needed according to the following table:

| Number of Strips | Wash Buffer Concentrate (20x) (mL) | Distilled Water (mL) |
|------------------|--|----------------------|
| 1–6 | 25 | 475 |
| 1–12 | 50 | 950 |

Assay buffer (1x)

- Pour the entire contents (5 mL) of the Assay Buffer Concentrate (20x) into a clean 100 mL graduated cylinder. Bring to final volume of 100 mL with distilled water. Mix gently to avoid foaming.
- 2. Store at 2-8°C. The Assay Buffer (1x) is stable for 30 days.
- 3. Assay Buffer (1x) may also be prepared as needed according to the following table:

| Number of Strips | Assay Buffer Concentrate (20x) (mL) | Distilled Water (mL) |
|------------------|---|----------------------|
| 1-6 | 2.5 | 47.5 |
| 1–12 | 5.0 | 95.0 |

Biotin-Conjugate

Note: The Biotin-Conjugate should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated Biotin-Conjugate solution with Conjugate Diluent in a clean plastic tube as needed according to the following table:

| Number of Strips | Biotin-Conjugate (mL) | Conjugate Diluent (mL) |
|------------------|-----------------------|------------------------|
| 1 - 6 | 0.06 | 5.94 |
| 1 - 12 | 0.12 | 11.88 |

Streptavidin-HRP

Note: The Streptavidin-HRP should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated Streptavidin-HRP solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

| Number of Strips | Streptavidin-HRP (mL) | Assay Buffer (1x) (mL) |
|------------------|-----------------------|------------------------|
| 1 - 6 | 0.06 | 5.94 |
| 1 - 12 | 0.12 | 11.88 |

Human IL-33 standard

- Reconstitute human IL-33 standard by addition of Calibrator Diluent Reconstitution volume is stated on the label of the standard vial. Swirl or mix gently to insure complete and homogeneous solubilization (concentration of reconstituted standard = 500 pg/mL).
- Allow the standard to reconstitute for 10-30 minutes. Mix well prior to making dilutions.
- After usage remaining standard cannot be stored and has to be discarded.

External standard dilution

- 1. Label 6 tubes, one for each standard point: S2, S3, S4, S5, S6, S7.
- 2. Prepare 1:2 serial dilutions for the standard curve as follows: Pipet 150 μL of Calibrator Diluent into each tube.
- 3. Pipet 150 μ L of reconstituted standard (serves as highest standard S1 = 500 pg/mL) into the first tube, labeled S2, and mix (concentration of standard 2 = 250 pg/mL).
- 4. Pipet 150 μ L of this dilution into the second tube, labeled S3, and mix thoroughly before the next transfer.
- 5. Repeat serial dilutions 4 more times thus creating the points of the standard curve (see Figure 7).

Calibrator Diluent serves as blank.




Fig. 7 Dilute standards - tubes

Test protocol

- Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Each sample, standard, blank and optional control sample should be assayed in duplicate. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2–8°C sealed tightly.
- 2. Wash the microwell strips twice with approximately $400~\mu$ L Wash Buffer per well with thorough aspiration of microwell contents between washes. Allow the Wash Buffer to sit in the wells for about 10–15 seconds before aspiration. Take care not to scratch the surface of the microwells.
 - After the last wash step, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess Wash Buffer. Use the microwell strips immediately after washing. Alternatively, microwell strips can be placed upside down on a wet absorbent paper for not longer than 15 minutes. Do not allow wells to dry.
- 3. Add 50 µL of Sample Diluent to all wells.
- 4. Add 50 μ L of each prepared Standard dilution in duplicate to the corresponding standard well (see Table 1).

Table 1 Example of the arrangement of blanks, standards, and samples in the microwell strips.

| | 1 | 2 | 3 | 4 |
|---|---------------------------|---------------------------|----------|----------|
| А | Standard 1 500.0 pg/mL | Standard 1 500.0 pg/mL | Sample 1 | Sample 1 |
| В | Standard 2 250.0 pg/mL | Standard 2 250.0 pg/mL | Sample 2 | Sample 2 |
| С | Standard 3 125.0 pg/mL | Standard 3 125.0 pg/mL | Sample 3 | Sample 3 |
| D | Standard 4 62.5 pg/mL | Standard 4 62.5 pg/mL | Sample 4 | Sample 4 |
| Е | Standard 5 31.3 pg/mL | Standard 5 31.3 pg/mL | Sample 5 | Sample 5 |
| F | Standard 6 15.6pg/mL | Standard 6 15.6pg/mL | Sample 6 | Sample 6 |
| G | Standard 7 7.8 pg/mL | Standard 7 7.8 pg/mL | Sample 7 | Sample 7 |
| Н | Blank | Blank | Sample 8 | Sample 8 |

- 5. Add 50 µL Calibrator Diluent to the blank wells.
- 6. Add 50 $\mu L~\mu L$ of each sample in duplicate to the sample wells (see Table 1).
- 7. Cover with an adhesive film and incubate at room temperature (18–25°C) for 2 hours on a microplate shaker. (Shaking is absolutely necessary for an optimal test performance.)
- **8.** Prepare Biotin-Conjugate (see "Biotin-Conjugate" on page 3).
- **9.** Remove adhesive film and empty wells. Wash microwell strips 6 times according to step 2. Proceed immediately to the next step.
- 10. Add 100 µL of Biotin-Conjugate to all wells.
- 11. Cover with an adhesive film and incubate at room temperature (18–25°C) for 1 hour on a microplate shaker. (Shaking is absolutely necessary for an optimal test performance.)
- **12.** Prepare Streptavidin-HRP (see "Streptavidin-HRP" on page 3).
- **13.** Remove adhesive film and empty wells. Wash microwell strips 6 times according to step 2. Proceed immediately to the next step.
- 14. Add 100 μ L of diluted Streptavidin-HRP to all wells, including the blank wells.
- 15. Cover with an adhesive film and incubate at room temperature (18–25°C) for 1 hour on a microplate shaker. (Shaking is absolutely necessary for an optimal test performance.)
- Remove adhesive film and empty wells. Wash microwell strips
 times according to step 2. Proceed immediately to the next step.
- 17. Pipet 100 µL of TMB Substrate Solution to all wells.

- **18.** Incubate the microwell strips at room temperature (18–25°C) for about 30 minutes. Avoid direct exposure to intense light.
 - The color development on the plate should be monitored and the substrate reaction stopped (see next step) before positive wells are no longer properly recordable. Determination of the ideal time period for color development has to be done individually for each assay.
 - It is recommended to add the stop solution when the highest standard has developed a dark blue color. Alternatively the color development can be monitored by the ELISA reader at 620 nm. The substrate reaction should be stopped as soon as Standard 1 has reached an OD of 0.9–0.95.
- 19. Stop the enzyme reaction by quickly pipetting $100~\mu L$ of Stop Solution into each well. It is important that the Stop Solution is spread quickly and uniformly throughout the microwells to completely inactivate the enzyme. Results must be read immediately after the Stop Solution is added or within one hour if the microwell strips are stored at $2-8^{\circ}C$ in the dark.
- 20. Read absorbance of each microwell on a spectrophotometer using 450 nm as the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 650 nm is acceptable). Blank the plate reader according to the manufacturer's instructions by using the blank wells. Determine the absorbance of both the samples and the standards.

Note: In case of incubation without shaking the obtained O.D. values may be lower than indicated below. Nevertheless the results are still valid.

Calculation of results

- Calculate the average absorbance values for each set of duplicate standards and samples. Duplicates should be within 20 percent of the mean value.
- Create a standard curve by plotting the mean absorbance for each standard concentration on the ordinate against the human IL-33 concentration on the abscissa. Draw a best fit curve through the points of the graph (a 5-parameter curve fit is recommended).
- To determine the concentration of circulating human IL-33 for each sample, first find the mean absorbance value on the ordinate and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the abscissa and read the corresponding human IL-33 concentration.
- If instructions in this protocol have been followed, samples have not been diluted and the concentration read from the standard curve must not be multiplied by a dilution factor.
- Calculation of samples with a concentration exceeding standard may result in incorrect, low human IL-33 levels. Such samples require further external predilution according to expected human IL-33 values with Sample Diluent in order to precisely quantitate the actual human IL-33 level.
- It is suggested that each testing facility establishes a control sample of known human IL-33 concentration and runs this additional control with each assay. If the values obtained are not within the expected range of the control, the assay results may be invalid.

A representative standard curve is shown in Figure 8.

Note: Do not use this standard curve to derive test results. Each laboratory must prepare a standard curve for each group of microwell strips assayed.




Fig. 8 Representative standard curve for Human IL-33 ELISA Kit. Human IL-33 was diluted in serial 2-fold steps in Calibrator Diluent.

Table 2 Typical data using the Human IL-33 ELISA Kit (measuring wavelength of 450 nm, reference wavelength of 620 nm).

| wavelength of 400 mm, reference wavelength of 020 mm, | | | | |
|---|---|-------------------|------------------------|----------|
| Standard | Human IL-33 concentration (pg/mL) | 0.D. at 450 nm | Mean O.D. at 450 nm | C.V. (%) |
| 1 | 500.0 | 2.489 2.583 | 2.536 | 2.6 |
| 2 | 250.0 | 1.257 1.475 | 1.366 | 11.3 |
| 3 | 125.0 | 0.801 0.811 | 0.806 | 0.9 |
| 4 | 62.5 | 0.449 0.442 | 0.446 | 1.0 |
| 5 | 31.3 | 0.259 0.265 | 0.262 | 1.7 |
| 6 | 15.6 | 0.183 0.185 | 0.184 | 1.0 |
| 7 | 7.8 | 0.123 0.141 | 0.132 | 9.6 |
| Blank | 0 | 0.074 0.082 | 0.078 | 7.2 |

The OD values of the standard curve may vary according to the conditions of assay performance (e.g., operator, pipetting technique, washing technique, or temperature effects). Furthermore shelf life of the kit may affect enzymatic activity and thus color intensity. Values measured are still valid.

Limitations

- Since exact conditions may vary from assay to assay, a standard curve must be established for every run.
- Bacterial or fungal contamination of either screen samples or reagents or cross-contamination between reagents may cause erroneous results.

- Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.
- Improper or insufficient washing at any stage of the procedure will
 result in either false positive or false negative results. Empty wells
 completely before dispensing fresh wash solution, fill with Wash
 Buffer as indicated for each wash cycle and do not allow wells to
 sit uncovered or dry for extended periods.

Performance characteristics

Sensitivity

The limit of detection of human IL-33 defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 0.9 pg/mL (mean of 6 independent assays).

Reproducibility

Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human IL-33. Two standard curves were run on each plate. Data below show the mean human IL-33 concentration and the coefficient of variation for each sample. The calculated overall intra-assay coefficient of variation was 4.7%

Table 3 The mean human IL-33 concentration and the coefficient of variation for each sample.

| Sample | Experiment | Mean human IL-33 concentration (pg/mL) | Coefficient of variation (%) |
|--------|------------|--|------------------------------|
| | 1 | 131.89 | 3.4 |
| 1 | 2 | 142.36 | 1.2 |
| | 3 | 141.34 | 2.5 |
| | 1 | 64.37 | 4.0 |
| 2 | 2 | 64.28 | 3.1 |
| | 3 | 71.24 | 3.5 |
| | 1 | 29.71 | 1.3 |
| 3 | 2 | 30.30 | 4.9 |
| | 3 | 32.68 | 6.1 |
| | 1 | 13.37 | 9.5 |
| 4 | 2 | 12.40 | 6.4 |
| | 3 | 13.21 | 6.5 |
| | 1 | 123.94 | 5.0 |
| 5 | 2 | 137.08 | 3.2 |
| | 3 | 144.29 | 5.6 |
| | 1 | 65.01 | 6.5 |
| 6 | 2 | 60.92 | 5.5 |
| | 3 | 73.34 | 5.0 |
| | 1 | 28.04 | 1.6 |
| 7 | 2 | 25.09 | 5.3 |
| | 3 | 30.19 | 4.2 |
| | 1 | 11.18 | 7.5 |
| 8 | 2 | 9.37 | 8.0 |
| | 3 | 11.00 | 3.1 |

Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human IL-33. Two standard curves were run on each plate. Data below show the mean human IL-33 concentration and the coefficient of

variation calculated on 18 determinations of each sample. The calculated overall inter-assay coefficient of variation was 6.9%.

Table 4 The mean human IL-33 concentration and the coefficient of variation of each sample.

| Sample | Mean human IL-33 concentration (pg/mL) | Coefficient of variation (%) |
|--------|--|------------------------------|
| 1 | 138.53 | 4.2 |
| 2 | 66.63 | 6.0 |
| 3 | 30.89 | 5.1 |
| 4 | 13.00 | 4.0 |
| 5 | 135.11 | 7.6 |
| 6 | 66.42 | 9.5 |
| 7 | 27.77 | 9.2 |
| 8 | 10.52 | 9.5 |

Spike recovery

The spike recovery was evaluated by spiking 3 levels of human IL-33 into serum, plasma, and cell culture supernatant. Recoveries were determined with 4 replicates each.

| Sample | Spike high (%) | | Spike high (%) Spike medium (%) | | Spike low (%) | |
|------------------------------------|----------------|------|---------------------------------|------|---------------|------|
| matrix | Range | Mean | Range | Mean | Range | Mean |
| Serum | 74-88 | 79 | 64-79 | 69 | 66-77 | 67 |
| Plasma (citrate) | 59-73 | 68 | 46-66 | 57 | 29-46 | 38 |
| Plasma (heparin) | 79-85 | 82 | 78-87 | 82 | 69-87 | 76 |
| Cell culture supernat ant | | 92 | | 90 | | 73 |

Dilution parallelism

Serum, plasma, and cell culture supernatant samples with different levels of human IL-33 were analyzed at serial 2-fold dilutions with 4 replicates each. The recovery ranged from 78% to 118% with an overall recovery of 99%.

| Sample matrix | Recovery of | exp. val. (%) |
|-------------------------|-------------|---------------|
| Sample matrix | Range | Mean |
| Serum | 92–118 | 101 |
| Plasma (citrate) | 91–111 | 99 |
| Plasma (heparin) | 78-99 | 89 |
| Cell culturesupernatant | 106–107 | 107 |

Sample stability

Freeze-Thaw stability

Aliquots of serum samples were stored at -20°C and thawed 5 times, and the human IL-33 levels determined. There was no significant loss of human IL-33 immunoreactivity detected by freezing and thawing.

Storage stability

Aliquots of serum samples were stored at -20° C, $2-8^{\circ}$ C, room temperature, and at 37°C, and the human IL-33 level determined after 24 hours. There was no significant loss of human IL-33 immunoreactivity detected during storage at -20, $2-8^{\circ}$ C, and room temperature.

Specificity

The assay detects both natural and recombinant human IL-33. The cross-reactivity and interference of circulating factors of the immune system was evaluated by spiking these proteins at physiologically relevant concentrations into a human IL-33 positive sample. No cross-reactivity or interference was detected, notably not with IL-1 α , IL-1 β , and IL-18.

Expected values

There were no detectable human IL-33 levels found. Elevated human IL-33 levels depend on the type of immunological disorder.

Reagent preparation summary

Wash buffer (1x)

Add Wash Buffer Concentrate 20x (50 mL) to 950 mL distilled water.

| Number of Strips | Wash Buffer Concentrate (mL) | Distilled Water (mL) |
|------------------|---------------------------------|----------------------|
| 1–6 | 25 | 475 |
| 1–12 | 50 | 950 |

Assay buffer (1x)

Add Assay Buffer Concentrate 20x (5 mL) to 95 mL distilled water.

| Number of Strips | Assay Buffer Concentrate (mL) | Distilled Water (mL) |
|------------------|----------------------------------|----------------------|
| 1–6 | 2.5 | 47.5 |
| 1–12 | 5.0 | 95.0 |

Biotin-Conjugate

Make a 1:100 dilution of Biotin-Conjugate in Conjugate Diluent:

| Number of Strips | Biotin-Conjugate (mL) | Conjugate Diluent (mL) |
|------------------|-----------------------|------------------------|
| 1 - 6 | 0.06 | 5.94 |
| 1 - 12 | 0.12 | 11.88 |

Streptavidin-HRP

Make a 1:100 dilution of Streptavidin-HRP in Assay Buffer (1x):

| Number of Strips | Streptavidin-HRP (mL) | Assay Buffer (1x) (mL) |
|------------------|-----------------------|------------------------|
| 1 - 6 | 0.06 | 5.94 |
| 1 - 12 | 0.12 | 11.88 |

Human IL-33 standard

Reconstitute lyophilized human IL-33 standard with Calibrator Diluent. (Reconstitution volume is stated on the label of the standard vial.)

Test protocol summary

Note: If instructions in this protocol have been followed, samples have not been diluted and the concentration read from the standard curve must not be multiplied by a dilution factor.

- 1. Determine the number of microwell strips required.
- 2. Wash microwell strips twice with Wash Buffer.
- 3. Add $50\mu L$ Sample Diluent to all wells.
- Add 50 μL of prepared Standard dilutions in duplicate to standard wells.
- 5. Add 50 µL Calibrator Diluent to blank wells.
- **6.** Add 50 μL sample in duplicate to sample wells.
- 7. Cover microwell strips and incubate 2 hours at room temperature (18–25°C). (Shaking is absolutely necessary for an optimal test performance.)
- 8. Prepare Biotin-Conjugate.
- 9. Empty and wash microwell strips 6 times with Wash Buffer.
- 10. Add 100 μL Biotin-Conjugate to all wells.
- 11. Cover microwell strips and incubate 1 hour at room temperature (18–25°C). (Shaking is absolutely necessary for an optimal test performance.)
- 12. Prepare Streptavidin-HRP.
- 13. Empty and wash microwell strips 6 times with Wash Buffer.
- 14. Add 100 µL diluted Streptavidin-HRP to all wells.
- **15.** Cover microwell strips and incubate 1 hour at room temperature (18–25°C). (Shaking is absolutely necessary for an optimal test performance.)
- 16. Empty and wash microwell strips 6 times with Wash Buffer.

- 17. Add 100 μL of TMB Substrate Solution to all wells.
- **18.** Incubate the microwell strips for about 30 minutes at room temperature (18–25°C).
- 19. Add 100 µL Stop Solution to all wells.
- 20. Blank microwell reader and measure color intensity at 450 nm.

Customer and technical support

Visit **thermofisher.com/support** for the latest service and support information.

- Worldwide contact telephone numbers
- Product support information
 - Product FAQs
 - Software, patches, and updates
 - Training for many applications and instruments

- · Order and web support
- Product documentation
 - User guides, manuals, and protocols
 - Certificates of Analysis
 - Safety Data Sheets (SDSs; also known as MSDSs)

Note: For SDSs for reagents and chemicals from other manufacturers, contact the manufacturer.

Limited product warranty

Life Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies' General Terms and Conditions of Sale at www.thermofisher.com/us/en/home/global/terms-and-conditions.html. If you have any questions, please contact Life Technologies at www.thermofisher.com/support.



Bender MedSystems GmbH | Campus Vienna Biocenter 2 | 1030 Vienna, Austria
For descriptions of symbols on product labels or product documents, go to **thermofisher.com/symbols-definition**.

The information in this guide is subject to change without notice.

DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, THERMO FISHER SCIENTIFIC INC. AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.

Important Licensing Information: These products may be covered by one or more Limited Use Label Licenses. By use of these products, you accept the terms and conditions of all applicable Limited Use Label Licenses.

©2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. All other trademarks are the property of their respective owners.



16 April 2019